Haleon plc Form 6-K Summary
Business context and reporting period
Haleon plc filed a Form 6-K for May 2023, dated May 16, 2023. The filing contains a TR-1 notification of a major holding by GSK plc related to Haleon ordinary shares. It is not a quarterly or annual financial-results filing.
Key financial and ownership metrics
- GSK plc’s resulting voting interest was 10.35%, representing 955,320,110 voting rights.
- The prior reported position was 12.94%; the filing therefore reflects a reduction of 2.59 percentage points.
- The interest was held indirectly through controlled GSK entities and the custodian Vidacos Nominees Limited.
- No revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics are provided in the filing.
Material changes versus the prior comparable position
GSK plc reported that its voting interest declined from 12.94% to 10.35% after the threshold was crossed on May 12, 2023. The change resulted from the sale by Glaxo Group Limited, a wholly owned subsidiary of GSK plc, of part of its Haleon holding.
Guidance, outlook, risks, and unusual items
The filing provides no management guidance, business outlook, operating commentary, contingencies, or financial risk discussion. The principal disclosed event is GSK’s partial disposal of its Haleon stake.
Investor verification points
- Verify the number of Haleon voting rights outstanding used to calculate the 10.35% interest.
- Confirm the ownership chain and the distinction between legal title held by Vidacos Nominees Limited and beneficial interests held through GSK entities.
- Review subsequent holding notifications for any further GSK disposals or changes in voting interest.
- Refer to Haleon’s latest results filing for operating performance, leverage, liquidity, and current guidance, which are not included here.